Elucidating cancer cachexia-mediated aberrant cardiac wasting signaling in human iPSC-derived cardiac muscle
Nora HosnyiD, Houda CoheniD, Mohamed Waleed Elafany, Jeff Schreifels, John BaueriD, Rishi GulatiiD, Brian R. ThompsoniD, Julia C. LiuiD, Joseph M. MetzgeriD
Abstract
Cancer cachexia is a highly debilitating clinical syndrome of involuntary body mass loss featuring profound muscle wasting leading to high mortality. Notably, cardiac wasting is prominent in cancer patients and cancer survivors. Cachexia studies present significant challenges due to the absence of human models and mainly short-term animal studies. To address this translational gap, we have developed a robust human-based cachexia experimental approach characterized by marked cardiac muscle wasting and contractile dysfunction, with increased expression of protein degradation markers. Using human iPSC-derived cardiac muscle, we investigated morphological, functional, and metabolic alterations in the key stages of cachexia and in the post-cachexia phase. C26 and HCT116 tumor cell lines were used to induce cachexia by two methods, pulse addition of cancer cell conditioned media or in transwell-adapted co-culture. Cachectic cardiac myocytes exhibited reduced contraction amplitude, prolonged relaxation time, and increased oxygen consumption rate (OCR), as assessed by video-based and Seahorse analyses. Mechanistic investigations centered on the Atrogin-1/Calcineurin A/NFAT axis revealed this signaling pathway as a central driver of cachexia-induced cardiac atrophy. Cachectic cardiac myocytes exhibited significant upregulation of Atrogin-1, leading to a marked decrease in Calcineurin A protein levels. This, in turn, impaired nuclear translocation of NFAT, thereby suppressing its transcriptional activity and downstream cell growth signaling. These molecular changes were accompanied by increased autophagic flux, as indicated by elevated LC3BII/LC3BI ratios. Furthermore, withdrawal of cachexia-inducing stimuli followed by regular media changes for one week led to normalization of Atrogin-1 and autophagy markers; however, functional impairments and metabolic dysregulation persisted, highlighting delayed recovery. Our new findings establish the Atrogin-1/Calcineurin A/NFAT axis as a key regulatory mechanism in cardiac muscle wasting and suggest this aberrant signaling axis may serve as a targetable mechanism for treatment of cachexia-induced cardiac dysfunction. Graphical Abstract O_FIG O_LINKSMALLFIG WIDTH=154 HEIGHT=200 SRC="FIGDIR/small/670675v2_ufig1.gif" ALT="Figure 1"> View larger version (31K): org.highwire.dtl.DTLVardef@12e9borg.highwire.dtl.DTLVardef@19ad494org.highwire.dtl.DTLVardef@1fa664corg.highwire.dtl.DTLVardef@5232a6_HPS_FORMAT_FIGEXP M_FIG C_FIG
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 3
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Cardiac atrophy, dysfunction, and metabolic impairments: a cancer-induced heart failure phenotype
L. M. Ogilvie, L. J. Delfinis, … J. A. Simpson·bioRxiv·Sep 30, 2023
- Stage-specific muscle wasting mechanisms in a novel cancer cachexia mouse model for ovarian granulosa cell tumor
Y. Zhang, J. Zhu, … T. Woodruff·bioRxiv·Jun 16, 2020
- Furan fatty acid supplementation protects against muscle atrophy during cancer cachexia
Anaïs Deglos, Jennifer Falconi, … François Casas·bioRxiv·Sep 10, 2026
- Impaired Barrier Integrity of the Skeletal Muscle Vascular Endothelium Drives Progression of Cancer Cachexia
Y.-M. Kim, M. A. Sanborn, … J. Rehman·Nature CancerPeer-reviewed·May 26, 2025
- The TWEAK/Fn14 signaling promotes skeletal muscle wasting during cancer cachexia
Meiricris Tomaz da Silva, Anirban Roy, … Ashok Kumar·iSciencePeer-reviewed·May 30, 2025
- Mathematical Model of Muscle Wasting in Cancer Cachexia
S. Farhang-Sardroodi, K. P. Wilkie·bioRxiv·Mar 30, 2020